Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Ricky W Johnstone" Clear advanced filters

  • Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy: both recombinant TRAIL and monoclonal antibodies that target these receptors have entered clinical trials. How are these agents faring? What are the current stumbling blocks?

    • Ricky W. Johnstone
    • Ailsa J. Frew
    • Mark J. Smyth
    Reviews
    Nature Reviews Cancer
    Volume: 8, P: 782-798

  • This review summarizes the state of the art in chemical probes targeting molecular processes operating at the chromatin interface in cancer cells. It seeks to provide a chemical toolbox for use by scientists to dissect epigenetic vulnerabilities of tumour biology.

    • Jake Shortt
    • Christopher J. Ott
    • James E. Bradner
    Reviews
    Nature Reviews Cancer
    Volume: 17, P: 160-183

  • Histone deacetylases (HDACs) are a class of epigenetic enzymes that remove acetyl groups from lysine residues on histones and other proteins. In this Review, the authors highlight the role of HDACs in cancer, neurological diseases and immune disorders, and discuss the development of small-molecule inhibitors.

    • Katrina J. Falkenberg
    • Ricky W. Johnstone
    Reviews
    Nature Reviews Drug Discovery
    Volume: 13, P: 673-691